Investors

Overview

Corporate Profile

At Gamida Cell, we are cell therapy pioneers working to turn cells into powerful therapeutics. Our proprietary technology leverages nicotinamide (NAM), which plays a key role in the metabolic reprogramming of cells, to expand the number of cells and enhance cellular functionality and phenotype. Our therapeutic product and candidates aim to offer potentially curative treatment options for patients living with blood cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Oct 02, 2023

Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa

Read More
Sep 28, 2023

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Read More
Sep 27, 2023

First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)

Read More
Aug 31, 2023

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

Read More
Aug 14, 2023

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Read More
Aug 01, 2023

Gamida Cell to Report Second Quarter 2023 Financial Results

Read More
Jul 11, 2023

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)

Read More
Jun 14, 2023

Gamida Cell To Host Investor Day

Read More
May 31, 2023

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
May 31, 2023

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Read More
May 22, 2023

Gamida Cell Appoints Terry Coelho as CFO

Read More
May 15, 2023

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Read More
May 11, 2023

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

Read More
Apr 19, 2023

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

Read More
Apr 18, 2023

Gamida Cell Announces Launch of Public Offering of Securities

Read More
Apr 17, 2023

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Read More
Mar 27, 2023

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Read More
Mar 20, 2023

Gamida Cell Announces Changes to Board of Directors

Read More
Mar 20, 2023

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

Read More
Mar 07, 2023

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

Read More
Upcoming Events
More events are coming soon.
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Ryan Pugliares
Gamida Cell Ltd.
IRPR@gamida-cell.com